

## **Stimulant approval criteria recommendations approved by HPSM P&T**

Medications: Short acting stimulants such as

- Amphetamine salts (Adderall)
- Dexmethylphenidate (Focalin)\*
- Dextroamphetamine (Dexedrine)
- Methamphetamine (Desoxyn)
- Methylphenidate (Ritalin)

Covered Uses: FDA approved indications

Required Medical Information:

1. If age >21, criteria must be met to start stimulant therapy per BHRS Adult ADHD Guidelines
2. Updated CURES report that does not indicate diversion or misuse (can be obtained by reviewing pharmacist)
3. Urine Tox screen (see Criteria below)

Age restriction: Code 1 for ADD/ADHD between ages 4-21; PA required for age >21

Coverage Duration: 30-90days depending on criteria below

Approval Criteria:

1. Treatment initiation phase: approve 90 days to titrate to stable dose, recommend switch over to long-acting formulation and consolidation to one class of stimulant medication
2. Continuation past 90 days: allow only if member
  - a. cannot tolerate side effects of long-acting stimulant, or
  - b. has long-acting formulation for morning, but need short-acting formulation once either in the morning or afternoon
  - c. with sound justification for a combination of amphetamine and methylphenidate class
3. If dosing beyond FDA max or more frequent than 3 times/day (>#90/30DS), approve 30 days and require Urine Tox screen to be submitted for continuation
4. If requesting more than one stimulant, approve 30 days for both and request MD to consolidate to one stimulant and submit Urine Tox screen for continuation except clear justification is indicated for a combination of amphetamine and methylphenidate class of medications
5. Member stable on short-acting stimulants will only receive 12 month approval if dosing and frequency within FDA range, and meet Criteria #2 above.

Medications: Long acting stimulants such as

- Amphetamine salts XR (Adderall XR)
- Dexmethylphenidate ER (Focalin XR)\*
- Dextroamphetamine ER (Dexedrine Spansule)
- Methylphenidate ER (Concerta, Metadate ER/CD, Ritalin SR/LA)

Covered Uses: FDA approved indications

Required Medical Information:

1. If age >21, criteria must be met to start stimulant therapy per BHRS Adult ADHD Guidelines
2. Updated CURES report that does not indicate diversion or misuse (can be obtained by reviewing pharmacist)
3. Urine Tox screen (see Criteria below)

Age restriction: Code 1 for ADD/ADHD between ages 4-21; PA required for age >21

Coverage Duration: 12 months

Criteria:

1. If dosing beyond FDA max or more frequent than QD (>#30/30DS), approve 30 days and require Urine Tox screen to be submitted for continuation, except occasionally BID dosing could be approved with justified clinical reasons
2. If requesting more than one stimulant, approve 30 days for both and request MD to consolidate to one stimulant and submit Urine Tox screen for continuation except clear justification is indicated for a combination of amphetamine and methylphenidate class of medications

\*See additional PA approval criteria for Focalin and Focalin XR

Approved by HPSM P&T on April 12, 2017